| Dr Torunn Yock, MD | |
|
100 Blossom St, Cox 3, Boston, MA 02114-2606 | |
| (617) 724-1548 | |
| (617) 726-3603 |
| Full Name | Dr Torunn Yock |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 26 Years |
| Location | 100 Blossom St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144203985 | NPI | - | NPPES |
| 2005701 | Medicaid | MA | |
| J25990 | Other | MA | BCBS MA |
| 203967 | Other | MA | TUFTS HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 203967 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | Hospital |
| Emerson Hospital - | W concord, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
| The General Hospital Corporation | 6507803806 | 1054 |
News Archive
MedCision, a leader in the automation of pre-clinical and clinical processes, today announced the company's participation in Phacilitate Cell and Gene Therapy 2017, a conference with the most comprehensive cell and gene therapy agenda in the industry.
A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore.
A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.
Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.
› Verified 2 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
MedCision, a leader in the automation of pre-clinical and clinical processes, today announced the company's participation in Phacilitate Cell and Gene Therapy 2017, a conference with the most comprehensive cell and gene therapy agenda in the industry.
A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore.
A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.
Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.
› Verified 2 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
MedCision, a leader in the automation of pre-clinical and clinical processes, today announced the company's participation in Phacilitate Cell and Gene Therapy 2017, a conference with the most comprehensive cell and gene therapy agenda in the industry.
A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore.
A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.
Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Torunn Yock, MD Po Box 9142, Charlestown, MA 02129-9142 Ph: (617) 724-1836 | Dr Torunn Yock, MD 100 Blossom St, Cox 3, Boston, MA 02114-2606 Ph: (617) 724-1548 |
News Archive
MedCision, a leader in the automation of pre-clinical and clinical processes, today announced the company's participation in Phacilitate Cell and Gene Therapy 2017, a conference with the most comprehensive cell and gene therapy agenda in the industry.
A new way to use MRI scans may help determine whether dementia is Alzheimer's disease or another type of dementia, according to new research published in the December 26, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore.
A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.
Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.
› Verified 2 days ago
Jennifer Michelle Thomas, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Department Of Radiology, Boston, MA 02115 Phone: 617-732-6248 | |
Dr. Meghavi Mashar, MB BCHIR Radiology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Rafeeque A Bhadelia, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Bidmc Wcc90, Boston, MA 02215 Phone: 617-754-2058 Fax: 617-754-2004 | |
Dr. Srinivasan Mukundan Jr., M.D. Radiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Brigham And Women's Hospital, Boston, MA 02115 Phone: 617-732-7260 | |
Raymond W Liu, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Grb 293, Boston, MA 02114 Phone: 917-923-2079 | |
Dr. Hillary R. Kelly, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Grb-273a, Boston, MA 02114 Phone: 617-726-8320 Fax: 617-724-3338 | |
Dr. Tina Young Poussaint, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6450 |